NCT05168423View on ClinicalTrials.gov

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

December 19, 2039

Study Completion Date

December 19, 2039

Conditions
Glioblastoma
Interventions
DRUG

CART-EGFR-IL13Ra2 Cells

autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Kite Pharma (a Gilead Company)

UNKNOWN

lead

University of Pennsylvania

OTHER